🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. Ondansetron Aurobindo 8 mg Filmtabletten, Dexamethasone 4 mg tablets, ZYPREXA 2.5 mg coated tablets, SELINEXOR, Bortezomib Accord 3.5 mg powder for solution for injection

    Karyopharm Therapeutics Inc

    Penta-refractory multiple myeloma and triple-class refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  2. Ontruzant 420 mg powder for concentrate for solution for infusion, Oxaliplatin onkovis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    HER2-positive, localized esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  3. Oxaliplatin 5 mg/ml concentrate for solution for infusion, TEMOZOLOMIDE, TRAMETINIB, DISODIUM FOLINATE, Capecitabine Accord 300 mg film-coated tablets, Temozolomide SUN 5 mg hard capsules, RUCAPARIB, Mekinist 0.5 mg film-coated tablets, Temozolomide SUN 140 mg hard capsules, REGORAFENIB, Capecitabine Accord 300 mg film-coated tablets, TEMOZOLOMIDE, TEMOZOLOMIDE, Temozolomide SUN 20 mg hard capsules, RUCAPARIB, CABOZANTINIB, Capecitabine Accord 300 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets,

    Bristol-Myers Squibb Australia Pty Ltd

    Pan tumor

    phase 2 small molecule active

    1 trial

  4. Ozempic 0.25 mg solution for injection in pre-filled pen, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    The George Institute

    Craving for and use of chemsex-related drugs

    phase 2 small molecule active

    1 trial

  5. PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , Lenvatinib, BEVACIZUMAB , CAPECITABINE , CARBOPLATIN , FLUOROURACIL , OXALIPLATIN , GEMCITABINE , CISPLATIN , MK-7684A, Lenvatinib

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  6. PACLITAXEL , Lenvatinib, MK-4830, FAMOTIDINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PARACETAMOL , IRINOTECAN , -, Lenvatinib, -, MK-2870

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  7. PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Erbitux 5 mg/mL solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion

    Ningbo Cancer Hospital

    Head and neck squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  8. PACLITAXEL ALBUMIN-BOUND, PACLITAXEL , DOCETAXEL , Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion., mRNA-4157, CARBOPLATIN

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  9. PACLITAXEL, LIBTAYO 350 mg concentrate for solution for infusion., CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. PACLITAXEL, MaaT033, CISPLATIN, CARBOPLATIN, GEMCITABINE, PACLITAXEL, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, GEMCITABINE, PEMETREXED, BEVACIZUMAB, PACLITAXEL, DOCETAXEL, PEMETREXED, DOCETAXEL, BEVACIZUMAB, GEMCITABINE, CISPLATIN, VINORELBINE, PACLITAXEL, CARBOPLATIN, VINORELBINE, CARBOPLATIN, VINORELBINE, PEMETREXED, VINORELBINE, DOCETAXEL, GEMCITABINE, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, PEMETREXED, PEMETREXED, CISPLATIN, PEMETREXED, DOCETAXEL

    The George Institute

    Advanced non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  11. PARACETAMOL, Placebo to QUC398 150 mg/1 mL Solution for injection, QUC398, Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets

    Novartis Pharmaceuticals

    Knee osteoarthritis

    phase 2 small molecule active

    1 trial

  12. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. PEMETREXED DISODIUM, PACLITAXEL, CARBOPLATIN, CISPLATIN, PACLITAXEL ALBUMIN-BOUND, Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  15. PF-07248144, FULVESTRANT ZENTIVA 250 mg, solution injectable en seringue préremplie, PF-07248144

    Ningbo Cancer Hospital

    Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting

    phase 2 small molecule active

    1 trial

  16. PF-08634404, YERVOY 5 mg/ml concentrate for solution for infusion

    Pfizer Australia Pty Ltd

    Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  17. POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, DARZALEX 1800 mg solution for injection, DEXAMETHASONE, DEXAMETHASONE

    Wuhan Createrna Science and Technology Co., Ltd

    Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  18. PONATINIB, CYCLOPHOSPHAMIDE, VINCRISTINE, BESPONSA 1 mg powder for concentrate for solution for infusion, METHOTREXATE, PURINETHOL 50 mg compresse, PREDNISONE

    Fondazione Telethon ETS

    Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients

    phase 2 small molecule active

    1 trial

  19. POTELIGEO 4 mg/mL concentrate for solution for infusion

    KYOWA KIRIN AUSTRALIA PTY LTD

    Mycosis fungoides/Sezary syndrome recurrent

    phase 2 small molecule active

    1 trial

  20. PREDNISOLONE , MabThera 100 mg concentrate for solution for infusion, PREDNISONE , MabThera 500 mg concentrate for solution for infusion

    Pari Pharma GmbH

    Minimal Change Nephrotic Syndrom

    phase 2 small molecule active

    1 trial

  21. PROLEUKIN 18 millions U.I., poudre pour solution injectable, CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  22. PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion, Lifileucel, Cyclophosphamide Injection 1 g, FLUDARABINE

    Iovance Biotherapeutics B.V.

    Previously treated advanced melanoma

    phase 2 small molecule active

    1 trial

  23. PTC857, Placebo to match PTC857 60 mg/mL oral solution, Utreloxastat 62.5

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  24. PUL-042 Inhalation Solution

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources